We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mass Spectroscopy, MRI Reveal New View of Body’s Response to Infection

By LabMedica International staff writers
Posted on 20 Aug 2012
A new imaging advance offers a three-dimensional (3D) window into the body’s response to infection--and the ability to detect the proteins involved in the response--could lead to innovative new biomarkers and therapeutic agents for infectious diseases.

Vanderbilt University (Nashville, TN, USA) scientists from many fields combined magnetic resonance imaging (MRI) and imaging mass spectrometry to visualize the inflammatory response to a bacterial infection in mice. More...
The techniques, described June 14, 2012, in the journal Cell Host & Microbe, provide insights into the characteristics of proteins not previously involved in the inflammatory response.

Access to distinctive resources at Vanderbilt made the unprecedented 3D infection imaging possible, according to Eric Skaar, PhD, Ernest Goodpasture chair in pathology and one of the senior coauthors of the study. “The studies in this paper couldn’t have happened at any other university, because the resources simply don’t exist at most schools,” Dr. Skaar said.

The resources include animal imaging technologies available through the Vanderbilt University Institute of Imaging Science (VUIIS), directed by John Gore, PhD, and imaging mass spectrometry technologies available through the Mass Spectrometry Research Center (MSRC), directed by Richard Caprioli, PhD, Drs. Gore and Caprioli are also senior coauthors of the paper.

Dr. Skaar and his team were interested in imaging infection in 3D--in the whole animal--while also being able to identify the proteins that are generated at sites of infection. Imaging mass spectrometry is a unique technology that directly measures proteins, lipids, and other metabolites and maps their distribution in a biopsy or other tissue sample. Ahmed Attia, PhD, a former member of Dr. Skaar’s group now on the faculty at Cairo University (Egypt), infected mice with Staphylococcus aureus, he then brought the infected animals to Daniel Colvin, PhD, in the VUIIS, who imaged them with magnetic resonance imaging (MRI). Kaitlin Schroeder and Erin Seeley, PhD, in the MSRC then conducted imaging mass spectrometry studies.

Fusing the two technologies and multiple data sets accurately required the expertise of Kevin Wilson, MESc, in the VUIIS, who developed algorithms to show consolidated 3D views of the inflammatory response. “This is another example of the multimodality approach we have been pursuing in general within the Imaging Institute,” Dr. Gore said.

The technologies allow the investigators to see one image of an infected animal, look at how proteins of the immune system are responding, and identify where the infected tissue is located, according to Dr. Skaar. “Part of the strength of this work is not where the research is now, but where it allows us to go from here.”

The scientists’ strategy now is to identify “proteins that are important at the interface between the host and the pathogen-- the battleground between the immune system and the bacteria,” Dr. Skaar said. The researchers will study the proteins they identify to discover new biomarkers for infection, which could improve diagnostic tools, or new targets for therapeutic intervention.

The technologies available through the MSRC and the VUIIS will be useful for any investigator interested in imaging the inflammatory response, which has roles in infectious diseases, cancer and autoimmune diseases, according to Dr. Skaar. Moreover, although the technology is not noninvasive--as imaging mass spectrometry requires tissue sections--it could be applied to tissues removed from patients, such as tumors.

“Imaging mass spectrometry is extremely valuable for the discovery process because it does not require a target-specific reagent such as an antibody--that is, you do not have to know in advance what you’re looking for in order to correlate molecular changes with disease outcome,” Dr. Caprioli said. “An area of intense interest is the application of this technology to molecular pathology.”

Related Links:

Vanderbilt University




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.